fulvestrant has been researched along with Atherosclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, YX; Dhaliwal, B; Hibbert, B; Ma, X; McNulty, M; O'Brien, E; Ramirez, D; Rayner, K; Simard, T; Sun, J | 1 |
| Feng, Y; Luo, G; Mu, Q; Nilsson-Ehle, P; Pan, L; Shi, Y; Tang, Y; Wei, J; Xu, N; Yu, Y; Zhang, J; Zhang, X | 1 |
2 other study(ies) available for fulvestrant and Atherosclerosis
| Article | Year |
|---|---|
Attenuation of atherogenesis via the anti-inflammatory effects of the selective estrogen receptor beta modulator 8β-VE2.
Topics: Animals; Anti-Inflammatory Agents; Apolipoproteins E; Atherosclerosis; Disease Models, Animal; Estradiol; Estrogen Receptor beta; Female; Fulvestrant; Inflammation; Interleukin-1beta; Macrophages; Mice; Mice, Knockout; Organ Size; Ovariectomy; Tumor Necrosis Factor-alpha; Uterus | 2011 |
Estrogen upregulates hepatic apolipoprotein M expression via the estrogen receptor.
Topics: Animals; Apolipoprotein A-I; Apolipoproteins; Apolipoproteins M; Atherosclerosis; Cholesterol, HDL; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression; Hep G2 Cells; Humans; Lipocalins; Liver; Ovariectomy; Postmenopause; Rats; Receptors, Estrogen; RNA, Messenger; Up-Regulation | 2011 |